BIOMARCER-2

Protocol Title

BIOMARCER-2 – Biomarker informed optimal management of advanced RAS wild type colorectal cancer.

Purpose of the Study

Choosing the optimal therapy for patients with metastatic colorectal cancer is challenging. A number of factors are taken into consideration when selecting the most appropriate treatment plan, and include prior treatment, RAS/BRAF mutation status, mismatch repair status and primary tumour location.

This study will test colorectal tumour samples for a prognostic biomarker expression called amphiregulin (AREG) and epiregulin (EREG). These biomarkers indicate a possible sensitivity to cancer treatment known as anti-EGFR treatment. Patients who are determined to have high AREG and/or EREG expression levels for right sided RAS/BRAF wild-type, metastatic colorectal cancer will receive targeted treatment with anti-EGFR therapy. The study aims to demonstrate the progression free survival (PFS) benefit in those patients receiving anti-EGFR based treatment in the 2nd or later line setting.

Contact Email

GCT_BIOMARCER-2_Mailbox@gicancer.org.au

STUDY CHAIRS

Dr Shehara Mendis
Professor Peter Gibbs

DETAILED INFORMATION AVAILABLE

Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) please click here.

Funding

2021 Innovation Grant

Patients Recruited

Click here to access the table and view recruitment data on all AGITG open trials:

Open Trial Recruitment Table